Europe — EMA
Somavert (Pegvisomant)
Somavert (pegvisomant) is a growth hormone receptor antagonist used for acromegaly management. This injectable therapy helps regulate growth hormone levels in a
Request sourcing
What is Pegvisomant?
Somavert (pegvisomant) is a growth hormone receptor antagonist used for acromegaly management. This injectable therapy helps regulate growth hormone levels in adults. Ideal for those seeking effective acromegaly treatment options. Short-term relief from acromegaly symptoms is a common outcome.
What is Pegvisomant used for?
Somavert (pegvisomant) is prescribed to reduce growth hormone excess in adults with acromegaly. It blocks growth hormone receptors, helping manage symptoms like enlarged hands and feet. Patients often ask, 'what is pegvisomant used for' to address growth hormone-related conditions. This medication supports long-term symptom control in acromegaly management.
What are the side effects of Pegvisomant?
Somavert may help normalize growth hormone levels and reduce symptoms such as joint pain and swelling. Some users report improved energy levels and reduced soft tissue enlargement over time. Individual responses vary, and effects depend on consistent use and medical guidance.
What precautions apply to Pegvisomant?
Store Somavert (pegvisomant) in a refrigerator between 2°C and 8°C. Protect from light and avoid freezing. Keep out of reach of children and pets. Do not use if the solution is discolored or contains particles. Always follow healthcare provider instructions for safe handling and disposal.
What does Pegvisomant interact with?
Somavert may interact with insulin and other diabetes medications, requiring dose adjustments. Caution is advised when combining with CYP450 enzyme inhibitors or inducers. Alcohol and certain supplements may affect how Somavert works. Always inform your healthcare provider about all medications and supplements you are taking.
